On Oct. 1 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
FDA will hold three virtual public meetings on its recent proposal to mandate additional traceability records for certain foods deemed high-risk (see 2009220041), the agency said in a notice released Oct. 2. The all-day meetings will be held Nov. 6, Nov. 18 and Dec. 2. At the meetings, FDA will “provide information and facilitate comment so that stakeholders can better evaluate and provide input on the proposed rule,” the agency said. “There will be an opportunity for questions, as well as an opportunity for open public comment.” Advance registration for the meetings is required; information about registering is in the notice. Electronic comments must be submitted on or before Jan. 21, 2021.
On Sept. 30 the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
FDA has issued its weekly Enforcement Report for Sept. 30, listing the status of recalls and field corrections for food, cosmetics, tobacco products, drugs, biologics and devices. The report covers both domestic and foreign firms.
On Sept. 29 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Sept. 28 the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Sept. 25 the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Sept. 24 the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Sept. 23 the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
FDA has issued its weekly Enforcement Report for Sept. 23, listing the status of recalls and field corrections for food, cosmetics, tobacco products, drugs, biologics and devices. The report covers both domestic and foreign firms.